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Abstract
Chlamydia trachomatis (CT) is the most common agent of bacterial sexually transmitted in‐
fections, both in developed and developing countries. It clearly constitutes a major burden
on public health. Screening programs and current research are mainly focused on decreas‐
ing the high incidence of chlamydial infections as well as their associated morbidity.
The greater clinical impact of CT infections occurs in women of reproductive age. Acute CT
infections are often associated to urethritis, mucopurulent cervicitis, endometritis, salpingi‐
tis, and pelvic inflammatory disease (PID). A vast proportion of CT infections are likely un‐
derestimated because  of  their  asymptomatic  clinical  course.  This  leads  to  repeat  and
chronic  infections,  which  have  deleterious  impact  on  the  female  reproductive  health.
Among the complications of the CT chronic infections are PID, ectopic pregnancy, preterm
birth, tubal obstruction and female infertility, which are of great interest in the reproduc‐
tion field.
Keywords: Chlamydia trachomatis, intracellular pathogens, bacterial sexually transmitted
infections, tubal obstruction, female infertility
1. Introduction
Chlamydia trachomatis (CT) is the most frequent bacterial agent causing sexually transmitted
infections (STIs) worldwide. According to the latest World Health Organization (WHO) report,
approximately 100 million new infections occur annually [1]. According to the Centre for
Disease Control (CDC), around 1.4 million new CT cases were reported in 2013, only in the
United States [2].
In this chapter, we briefly present the current knowledge about the cell biology of the bacteria,
reviewing the mechanisms of establishment of CT intracellular niche, the inducers of persistent
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infections, and the pathogen factors that may be involved in the damage of female reproductive
tract. Then, we analyze the host factors that may contribute to the development of infertility,
mainly immune response and genetic predisposition, hormonal status, and sexual behavior.
Undiagnosed and untreated infections, repeat and persistent infections, and coinfections are
likely responsible for the detrimental sequelae on woman fertility of CT pathogenesis.
This chapter specially focuses on the consequences of chronic diseases after CT infections,
mainly pelvic inflammatory disease, tubal infertility, and adverse pregnancy outcome, which
are of therapeutic interest in the reproduction field.
2. The bacteria: Intracellular life cycle, Chlamydia trachomatis serovars and
virulence factors
2.1. Chlamydial developmental cycle and intracellular niche
CT is a highly evolved pathogen that has a reduced genome, first sequenced by Stephens and
collaborators in 1998. Its chromosome consists of approximately one million base pairs and
encodes for up to 600 proteins [3]. Analysis of chlamydial genes reveals that this bacterium
heavily depends on host cell for nutrition and replication, indicating a complex evolution for
adaptation to an obligate intracellular lifestyle.
CT has tropism for genital mucosal epithelium, which promotes its own uptake into non-
phagocytic cells. Chlamydial infection and propagation rely upon a unique biphasic life cycle
that begins by contact of infectious, environmentally resistant, elementary bodies (EBs) with
the apical surface of the epithelial cell. Several mechanisms are involved in the invasion of host
cell, likely parasite-specified phagocytosis and receptor-mediated endocytosis [4]. Multiple
receptors have been proposed to mediate the interaction between the EB and the host cell,
among them, the mannose receptor, the mannose 6-phosphate receptor, and the estrogen
receptor [5]. Other host molecules such as heparan sulfate proteoglycans [6,7], and protein
disulfide isomerase also participate in EB binding to the eukaryotic cells [8]. Concomitantly,
multiple bacterial adhesins and ligands such as glycosaminoglycan [9], the major outer
membrane protein (MOMP) [10], OmcB [11], and PmpD [12] facilitate EB attachment to host
cells. Translocated actin-recruiting phosphoprotein (TARP) is a bacterial protein that nucleates
actin and promotes host cell cytoskeleton remodeling to force bacterium uptake [13–15].
The infectious EBs enter the host cell in membrane-bound vesicles that travel toward the
perinucleus and fuse to form a single vacuole termed the inclusion. Once inside this modified
phagosome, EBs differentiate into metabolically active but non-infectious reticulate bodies
(RBs) that are the replicative bacterial forms. RBs asynchronously multiply by binary fission
within the confines of the growing inclusion. After numerous rounds of replication, RBs re-
differentiate back into infectious EBs to be ready for spreading to adjacent cells [16,17]. The
ability of CT to cycle between resting and replicating organisms accounts for a drawback in
the eradication of this intracellular pathogen. Finally, the infectious bacteria are released by
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two independent mechanisms, the host cell lysis, or the extrusion of the inclusion [18]. A
scheme of chlamydial developmental life cycle is shown in Figure 1.
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Figure 1. Chlamydia trachomatis developmental cycle. Chlamydial infection begins with attachment of the infectious
bacterial form, the elementary body (EB) to uncharacterized host cell receptors. Signal transduction events are trig‐
gered, and EBs entry into the host cell in small vesicles. These CT-containing vesicles are actively modified by the bac‐
teria; they travel toward the perinucleus and fuse to form a single vacuole named “the inclusion”. Once internalized,
EB differentiates into the replicative bacterial form, the reticulate body (RB), which multiplies by binary fission. At the
end, RBs re-differentiate to EBs that are released by host cell lysis or extrusion of the inclusion. The whole cycle is com‐
pleted in 40–72 hours. In a stressful environment, RBs enter a latent stage where it persists until more favorable grow‐
ing conditions. These aberrant bacteria (AB) are present in persistent and chronic infections.
In response to stress, CT enters into a low replicative viable state that is termed “persistent or
aberrant bacterial form”, which is able to resume normal replication as soon as conditions are
again favorable. Among the inducers of the persistent bacterial state stand the sphingolipid
deprivation and tryptophan lack, the presence of interferon gamma (IFN-γ), or certain
antibiotics such as penicillin. The evasion strategy has been linked to the capacity of these
bacteria to cause latent and chronic infections. Thus, the onset of the infection is generally not
detected and re-infection may occur, especially when infected couples are involved. Further‐
more, the fact that CT clearance is rarely followed up, combined with the ability of this
pathogen to persist, contributes to the occurrence of long-term infections [19].
Undoubtedly, an essential issue to chlamydial growth and development is the establishment
of its intracellular niche. Early chlamydial gene expression is required to inclusion generation,
to avoid immune system surveillance, and to hijack host cell functions [20]. These bacteria
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actively modify the inclusion membrane by exclusion or recruitment of selected host proteins,
mainly Rab proteins, the master controllers of intracellular traffic [16,21]. Increasing evidence
points out that the invading bacteria subvert trafficking not only to circumvent the lysosomal
degradative route but also to facilitate the delivery of host nutrients to the growing inclusion
[17,22]. As soon as the chlamydial inclusion is formed, it dissociates from the classical phag‐
ocytic pathway and barely interacts with endocytic vesicles [23]. Instead, chlamydial inclusion
intersects Golgi-derived vesicles [24–27], multivesicular bodies [28], and lipid droplets [29,30].
By this strategy, these bacteria take over the infected cell for sphingomyelin, cholesterol, and
neutral lipid acquisition like pirates [31–34]. In addition, CTs possess other mechanisms, such
as transporter molecules, finely adapted to acquire amino acids, nucleotides, and energy from
the host cell [22,35–38]. At present, the strategies developed by CTs to re-route intracellular
trafficking and to co-opt host cell functions for their benefit are being actively studied.
2.2. Bacterial genotypes and virulence factors
Different strains of CT have been described based on genome sequencing and the antigenic
properties of the major outer membrane protein (MOMP) [39]. There are more than 20 distinct
serovars (serologically variant strains) of CT currently identified, on the basis of monoclonal
antibody-based typing assays [40–42]. In general, CTs have been grouped into three main
pathobiotypes: ocular infections (serovars A to C), sexually transmitted diseases (D to K), and
lymphogranuloma venereum (L1 to L3). Serovars A, B, and C have tropism for the ocular
epithelium, causing from acute conjunctivitis to trachoma, a serious eye disease endemic in
Africa and Asia that is characterized by chronic conjunctivitis and can lead to infectious
blindness. Serovars D through K have emerged as the major causing agents of sexually
transmitted diseases. They preferentially infect squamocolumnar epithelial cells of female
reproductive system and the male genitourinary tract. E and D serovars are isolated from
genital tract infections with the most frequency worldwide. Occasionally, they cause conjunc‐
tivitis or pneumonia in newborns infected during labor. Serovars L1 to L3 are responsible for
a systemic illness, the lymphogranuloma venereum that is associated with genital ulcer disease
in tropical countries [43,44] (Table 1).
Chlamydia genotyping is useful to determine tissue tropism [45–47]. Several studies attempted
to directly link disease severity with CT serovars; however, they often failed because of small
number of samples and high variability in results [48]. Intensive research is conducted to
confidently associate CT serotypes to higher pathogenic potential, clinical course, or disease
outcome. Nevertheless, at present, bacterial ability to ascend and colonize female upper
reproductive tract is not clearly associated to a particular CT serovar.
On the other hand, CT gene polymorphisms determine distinct antigenic challenge to the
immune system [49]. Certain bacterial polymorphisms may induce an altered immune
response [50]. In consequence, they are able to cause immunological disorders, especially in
susceptible individuals. Chlamydial infections often precede the initiation of autoimmune
diseases, and frequently, these bacteria are found within autoimmune lesions. Bacterial
proteins similar to host self-proteins might be the underlying cause of diverse autoimmune
diseases [51,52]. This molecular mimicry may elicit an immune response to both self and
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microbial proteins. Chlamydial heat shock protein 60, DNA primase, and OmcB proteins
represent the strongest cases for molecular mimicry [53]. The most frequent autoimmune
diseases connected to chlamydial infections are intestinal inflammatory pathologies and
rheumatic or connective-tissue diseases [54,55]. Further research is required to unravel the
molecular machinery involved in the complex pathogen-host cell interaction.
Chlamydial strains and clinical diseases
Serovars Host Acute Chronic
A–C
Newborns
Conjunctivitis Trachoma
Both sexes
D–K
Newborn Ophthalmianeonatorum Neonatal pneumonia
Men Urethritis ProctitisEpididymitis
Women UrethritisCervicitis
Mucopurulent cervicitis
Pelvic inflammatory disease
Tubal infertility
Ectopic pregnancy
Premature rupture of membranes
Chorioamnionitis
Premature delivery
Puerperal infection
Cervical neoplasia
L1–3 Both sexes Lymphogranuloma venereum
Different serovars
and bacterial
polymorphism
Both sexes
Autoimmune diseases
Reactive arthritis
Collagenopathies
Reiter´s syndrome
Inflammatory bowel disease
Crohn´s disease
Table 1. Chlamydial serovars, tissue tropism and clinical diseases. Acute and chronic pathologies occur in men,
women and newborns following CT infections. Serovars A to C have tropism for ocular epithelium, causing from acute
conjunctivitis to infectious blindness or trachoma. Serovars D to K infect epithelial cells of the genitourinary system,
generating a broad range of acute and chronic pathologies that damage reproductive tissue and may infect newborns
during labor. Serovars L1–3 cause lymphogranuloma venereum. Several autoimmune diseases are associated to diverse
CT strains.
Several putative virulence factors have been postulated, including the polymorphic outer
membrane autotransporter family of proteins (pmp), type III secretion system (TTSS) effectors,
a large cytotoxin, and stress response proteins may contribute to increase the CT-associated
pathogenicity. Pmp proteins are strongly immunogenic and trigger pro-inflammatory
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cytokine responses [56]. Chlamydial TTSS effectors mediate the interaction with the host as
they are injected to the cytoplasm and alter host cell functioning [57–59]. Important TTSS
effectors are the inclusion (Inc) proteins that are bacterial proteins present at the inclusion
membrane. For instance, IncA promotes the fusion of individual CT-containing vesicles to
form a single inclusion [60,61]. Natural IncA bacterial mutants are associated with reduced
virulence [62]. Another TTSS effector is TARP, mentioned in the previous section, as a bacterial
protein that favors CT internalization via an actin recruiting mechanism [34,63]. Additionally,
a chlamydial cytotoxin glycosylates the eukaryotic protein Rac1, and thereby induces actin
reorganization and promotes the invasion of host cell [64,65]. Chlamydial glycolipid exoanti‐
gens [66] and the lipopolysaccharide [67] may constitute additional virulence factors. Other
proteins encoded by the cryptic plasmid or related to the ability of the bacteria to survive under
stressful metabolic conditions such as iron or tryptophan deprivation are thought to increase
virulence and pathogenicity [68,69]. Chlamydial stress proteins, GroEL and GroES, may
activate toll-like receptors and trigger a potent inflammatory response, injuring host repro‐
ductive tissues [70–73].
In addition to CT serovars and virulence molecules, other bacterial factors may be involved in
the pathogenicity and chlamydial infection outcome, such as the pathogen load, route of
infection, bacterial ability to enter persistent state, ascension capacity and strength to colonize
genital upper tract, resistance to antibiotic treatment, and so on. Further studies are needed to
determine the contribution of each bacterial factor to the development of severe damage on
the female reproductive system.
3. The host: Immunological and genetic factors, age and hormonal status,
and sexual behavior
3.1. Immunological and genetic factors
An important issue that contributes to CT pathogenesis is its remarkable ability to avoid the
host immune system. Several strategies are displayed by these bacteria to prevent immune
degradation, such as its intracellular lifestyle, its ability to escape from phagolysosomal
pathway, its resistance to interferon gamma (IFN-γ), among others lesser known bacterial
molecules. Actually, host immune response has opposite results on chlamydial infection
outcome. A low immune response generates a suitable environment for pathogen colonization,
while a strong immune response could lead to excessive inflammation and tissue damage.
Pathogens own characteristics in conjunction with host genetic susceptibility are important in
determining the severity of the illness.
At the site of invasion, an intense inflammation occurs, attracting different types of cells, such
as macrophages, neutrophils, T and B lymphocytes, natural killers, and dendritic cells. Locally,
there is an increased production of reactive oxygen species (ROS) that produces oxidative DNA
damage, lipid peroxidation, energy depletion, modulation of gene expression, and proteins
synthesis. Oxidative stress provokes pathologic changes that harm reproductive tissues. In
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addition, a broad collection of pro- and anti-inflammatory cytokines are released including
IFN-γ, tumor necrosis factor (TNF-α), interleukin (IL) IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8,
IL-10, IL-12, IL-13, IL-17, IL-22, vascular endothelial growth factor (VEGF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), and lactoferrin. These mediators trigger
cellular inflammatory responses that mediate direct damage to the tissues [74,75]. Most of them
are involved in the pathophysiology of tubal infertility, birth defects, and miscarriage [76].
In addition to the inflammatory response, CT infection evokes vigorous local and systemic
humoral and cell-mediated immune responses. Several CT-specific antibodies, IgG isotype
rather than secretory IgA, are found in circulation and in the cervicovaginal fluid of the female
genital tract. These antibodies can neutralize chlamydial antigens; nevertheless, they do not
assure  resolution  of  the  infection.  Antibodies  toward  the  bacterial  MOMP  protein  are
prevalent in primary chlamydial infections, whereas antibodies against CT-hsp10 and hsp60
are present in recurrent or persistent infections and correlate with severe sequelae such as
tubal infertility, ectopic pregnancy, and PID [77–79]. Regarding the cell-mediated immune
response, the T-helper lymphocytes type 1 (Th1) secrete IFN-γ, IL-2, and IL-12 and play a
role in the resolution of infection [80,81]. On the other hand, the T-helper lymphocytes type
2 (Th2), which support the humoral immune response, produces IL-4, IL-5, IL-6, and IL-10
and participates in the developing tubal scarring [82]. The inflammatory response occurs, at
the same extent, in both initial and repeat infections, whereas T-cell responses are predomi‐
nant in the latter ones [80,83].
Actually, host immune response is considered as one of the most important determinants in
chlamydial infection outcome. A delicate balance between pro- and anti-inflammatory
cytokines is needed to clear infection, avoiding tissue injuring. At this point, host genetic
predisposition is a major player of pathology and CT-related infertility development [84].
Host genetic polymorphisms may encode aberrant or dysfunctional toll-like receptors (TLR)
and nucleotide-binding oligomerization domain proteins (NOD) that do not appropriately
recognize CT. These individuals have an impaired bacterial clearance and a high risk to
develop an aberrant immune response, favoring CT persistence [85–88]. Identifying host
genetic factors and bacterial virulence factors involved in immunoevasion and immunopa‐
thology remains a major priority in research for preventing chlamydial infection and its
sequelae. Furthermore, the understanding of local innate and adaptive immune responses and
their actors along the genital tract will be crucial for designing new therapeutic approaches
and for developing a protective vaccine.
3.2. Age and hormonal status
CT preferentially targets young women at reproductive age. It has been reported that the
highest incidence occurs in women between 16 to 24 years [89]. Therefore, the impact on female
reproductive health is very important. Notwithstanding younger women are at higher risk of
contracting a chlamydial infection, the rates of developing PID increase with age, being more
frequent in the 30 to 40 decade [90]. After menopause, the frequency of chlamydial infections
decreases substantially [91].
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Accordingly, estrogen and progesterone are important for the establishment of chlamydial
infection. Furthermore, estrogen receptors have been involved in the internalization of CT
[92,93]. Sex hormones affect the clinical outcome of chlamydial infections; thus, follicle
stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P4), and
prolactin (PRL) are involved not only in the establishment of chlamydial infection but also in
the development of sequelae on reproductive tissue [94,95]. Additionally, oral contraceptive
use was found to be a risk factor for CT infection. Several studies have attempted to elucidate
the relation between the hormonal status at the time of infection and its contribution to tubal
occlusion in genital chlamydial infection. Unfortunately, the role of sex steroids in infection
outcome is far from being fully understood. Sex hormones have been shown to modulate
immune responses and to have antioxidant effects in the female genital tract [96–98]. However,
the mechanisms by which sex hormones may benefit or impair the colonization of genital
tissues by pathogenic microorganisms should be further investigated.
3.3. Sexual behavior and other host factors
Sexual initiation at young age and a higher number of sexual partners are associated with
increased risk of CT infection [99]. In a similar manner, having sex without protection favors
CT contagion. This sexual behavior is also associated with higher incidence of sexually
transmitted pathogens such as Neisseria gonorrhoeae, Candida albicans, Human Immunodeficiency
Virus, among others [100–103]. Taken together, unsafe and high-risk sexual conduct is linked
to impairment of women reproductive health, and particularly to tubal infertility. As it has
been previously mentioned, some women have a genotypic predisposition to develop an
abnormal immune response and severe inflammation following CT infection. In these women,
there is a high rate of tubal obstruction and CT-related infertility, independent of sexual
behavior [84].
In general, multiple sexual partners and unsafe intercourse increase the risk of CT recurrent
infections and coinfection with other sexually transmitted pathogens. Thereby, the high chance
to suffer repeat and chronic infections that target women reproductive tissue raises the
infertility-associated pathologies.
4. Pathogen-host interplay: Establishment of latent, repeat, and persistent
infections and coinfections
CT survival and replication heavily hinge on host cells. In fact, CT has evolved in relationship
with human cells. However, little is known about the molecular basis of CT interaction with
host epithelia and immune system. An increasing number of bacterial and host factors
interplay for the establishment of chlamydial infection and determine the pathologic profile
and clinical disease outcome. A simple scheme is shown in Figure 2 summarizing the main CT
and host factors that jointly with environmental factors and the failure in diagnosis and
treatment, lead to unsolved, latent, and long-term chlamydial infections.
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Figure 2. Bacterial and host factors involved in the development of female infertility. Bacterial factors such as CT geno‐
types and serovars, virulence factors, and pathogen burden, in conjunction with, host factors such as genetic predispo‐
sition and immune response, age and hormonal status, and sexual behavior participate in the establishment of the
infection and pathology. Other elements that take part in the development of CT-related diseases are microbiome and
coinfections with other sexually transmitted pathogens, environmental factors, and local prevalence, and most impor‐
tantly, the failure in diagnosis and treatment of chlamydial infections. Taken together, these factors sustain repeat and
persistent chlamydial infections that damage female reproductive health.
Microbiome (microbial flora present at the genital tract) and the presence of other sexually
transmitted pathogens may be important for the colonization of reproductive tissue and the
establishment of chlamydial infection. The presence of lactobacilli in the vagina confers
protection against the acquisition of chlamydial infection [104]. In contrast, indole-generating
bacteria present in the microbiome or bacterial vaginosis allow CT to synthesize tryptophan,
and consequently, to avoid the anti-chlamydial activity of IFN-γ [45,65]. Coinfections are more
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frequent in vaginosis and women with high-risk sexual behavior [100]. Clearly, coinfections
exacerbate host immune response and inflammation; therefore, they favor scarring and
sequelae on female reproductive system and increase the likelihood of tubal infertility.
The worst scenarios involve silent and latent infections that underline chronic persistent
chlamydial infection and frequent re-infections [1]. Chlamydial infections may persist in the
female upper genital tract for months in the absence of treatment. They are often asymptomatic
or alternate quiescent stages with periods of clinical manifestations [105]. Actually, chronic
chlamydial infections may be because of the reactivation of asymptomatic latently infected
deep-seated cells. The presence of aberrant bacterial forms responsible for chlamydial
persistence constitutes a long-time challenge to the immune system. Host immunopathological
response can damage the fallopian tube and generate female infertility [65,92].
Reinfections, persistent infections, and treatment failure account for repeat infections that
represent a substantial proportion of the chlamydial infections detected annually [106]. Repeat
infection is not the sole determinant of severe genital tract pathology and sequelae. However,
repeat infection increases the risk of developing tubal obstruction and female infertility [76].
Increasing evidence indicates that long-term persistence of viable aberrant chlamydial
organisms within host cells is associated with inflammatory and autoimmune diseases in
extragenital tissues.
In definitive, the pathogen-host interplay and the concurrency of exogenous factors appear to
be related to CT-induced immunopathology. In spite of the substantial worldwide impact of
chlamydial disease, the bacterial and host factors that result in infertility are still not clear.
Current efforts are focused on discovering what CT is doing to the host cells to prevent sequelae
and undesired consequences of infection.
5. Mechanisms of pathogenicity and clinical course
CT infects both sexes; however, chlamydial infections constitute primarily a female health
issue since the consequences are more damaging to the reproductive tissue in women than in
men. In males, CT can infect urethra, epididymis, prostate, seminal vesicles, and testis. Usually,
chlamydial infections are symptomatic, less frequent, and more easily eradicated in men than
in women. Nevertheless, chlamydial infection in the male genitourinary tract might induce
severe damage to seminiferous tubules, spermatogenesis, and sperm cells morphology that
can result in impaired male fertility [107].
Here, we focus on chlamydial infections occurring in women. In first world countries, 3 to 5%
of women younger than 30 years old will be infected by CT at any point in time [90,108]. And,
in over 70% of the cases, CT infection of the female genitourinary tract is asymptomatic,
spoiling the prevalence or incidence rates. Consequently, it is difficult to assess the incidence
of sequelae, mainly PID, tubal obstruction, and female infertility, attributable to genital CT
infection.
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In women, CT is the major cause of mucopurulent cervicitis (MPC) and PID. Other manifes‐
tations of chlamydial infections are vaginitis, urethritis, salpingitis, endometritis, tubo-ovarian
abscess, pelvic peritonitis, periappendicitis, and perihepatitis. The symptoms more frequently
reported consist of abdominal pain, dysuria, vaginal itching, and abnormal vaginal discharge.
However, the most important feature of chlamydial infection in the female genital tract is the
occurrence of asymptomatic infection that remains subclinical for long periods in a high rate
[109,110]. Asymptomatic ascending bacteria from the cervix may produce two groups of
pathologies: (i) PID-associated complications such as chronic pelvic pain, tubal obstruction,
and female infertility [111,112] and (ii) adverse pregnancy outcomes such as ectopic pregnancy,
miscarriage, premature rupture of membranes, chrioamnionitis, preterm birth, stillbirths, and
puerperal and neonatal infections [113–115].
General consensus in the medical community agrees that chlamydial PID is the most common
preventable cause of tubal infertility and adverse pregnancy outcome [1]. However, the lack
of systematic detection of the bacteria weakens these estimations, usually performed by
analysis of a reduced number of cases. Approximately 20% of women with chlamydial lower
genital tract infection will develop PID, 4% chronic pelvic pain, 3% tubal infertility, and 2%
adverse pregnancy outcome [107]. In developing countries, the incidence and prevalence of
CT infections and their harmful consequences on female reproductive tissue are not accurately
known since CT infection is not routinely screened.
There is conclusive evidence that women who have suffered PID have higher risk to develop
tubal infertility. A study demonstrated that 16.5% of women with abnormal laparoscopic
findings likely resulting of acute PID failed to conceive, in comparison to 2.7% in control
women; 10.8% developed tubal infertility, and 9.1% went through ectopic pregnancy. There‐
fore, PID increases the probability of permanent damage on female reproductive system. CT
is the most common causing agent of PID; however, a drawback of this analysis is the lack of
the identification of the infectious agent underlying the PID. Several randomized controlled
trials to assess the value of CT screening found it helpful to reduce the incidence of PID among
infected women [116–118]. The chance to develop tubal infertility after a single episode of PID
is around 10% [112]. Furthermore, each episode of PID doubled the risk of tubal damage [119]
independent of whether the infection was asymptomatic or not.
One of the most serious sequelae of PID and persistent chlamydial infections is the fibrosis
and scarring obstruction of the fallopian tubes that leads to tubal infertility. However, the risk
of tubal infertility due to CT infections is lower than PID incidence [76]. The proportion of
tubal infertility among all causes of infertility varies from 40% in first-world countries to 85%
in developing countries [1]. Undiagnosed and untreated chlamydial infections usually evolve
to long-term persistent infections, in which chlamydial antigens chronically stimulate the host
immune system. Abnormal humoral and cell-mediated immune responses and severe
inflammation have been implicated in the development of immunopathological damage of
fallopian tubes. Thus, the interaction between CT and the host becomes relevant for the illness
outcome. However, the exact pathologic mechanism of CT-induced tubal damage and tubal
infertility has not been elucidated yet.
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In addition, acute and chronic maternal chlamydial infections constitute a significant risk factor
for adverse pregnancy outcomes and newborns contagion. Untreated and persistent infections
are strongly associated with ectopic pregnancy, which is the tubal development of the embryo
and constitute the main cause of maternal mortality in the first trimester of pregnancy in
developing countries. In addition, miscarriage, chrioamnionitis, low birth weight, stillbirth,
premature rupture of membranes, and preterm birth are frequent pathological consequences
of chlamydial infections [51,113,114]. Several mechanisms may contribute to the development
of these pathologies, including direct fetal infection, placental damage, and severe puerperal
maternal illness [120–124]. Nevertheless, the exact nature of chlamydial infection pathogenesis
during pregnancy remains unexplained.
CT infections can also be vertically transmitted to newborns during labor, resulting in
chlamydial conjunctivitis and/or pneumonia, which may possibly involve similar pathogen‐
esis mechanisms to those occurring in the female genital tract.
Controversial reports point out CT as a risk factor for cervical carcinoma, independent of
human papillomavirus [107]. It has been shown that CT interferes with multiple proapoptotic
pathways to guarantee survival within host cells [125,126]. In addition, CT activates prosur‐
vival signaling pathways for bacterial nutrient acquisition, expression of antiapoptotic factors,
and synthesis of proinflammatory cytokines [127,128]. On the other hand, CT interferes with
chromosome segregation and cytokinesis. In consequence, multinucleated cells and cells with
aberrant number of chromosomes are often observed in cell cultures infected with CT [129].
Taken together, these findings suggest that persistent chlamydial infections might play a role
in the development of cervical neoplasia. Further research is needed to shed light to this issue.
The high prevalence and incidence estimates worldwide, in conjunction to the diversity of
clinical entities and long-term consequences of chlamydial infections, propel further research
of the bacterial and host factors involved in the pathogenesis and damage to the reproductive
system.
6. Important challenges: Prevention, diagnosis, and treatment of
chlamydial infections
The widespread incidence and prevalence of sexually transmitted infections, especially among
young population, made them a priority public-health concern worldwide. Screening, control
programmes, and education in sexual behavioral aspects and contraception are fundamental
for the prevention of chlamydial infections and their long-term sequelae, mainly PID and tubal
infertility.
Routine screening allows the identification of asymptomatic carriers of CT and contributes to
the early detection of chlamydial infections. Appropriated diagnostic services are required to
obtain reliable results. The most confident tests for the detection of CT involve nucleid acid
amplification techniques that are not available in all laboratories, especially in third-world
countries. Nucleic acid amplification tests are more sensitive than culture or antigen tests.
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Improvement in molecular diagnostics will lead to improvement in treatment and prevention
of damage to reproductive tissues. It has been shown that screening is cost-effective even in
low prevalence populations, due to the high costs of treatment of complications resulting from
undiagnosed and untreated chlamydial infections [130]. The implement of additional targeted
screening of women at risk will contribute to reduce the CT-associated infertility.
Additionally, clinicians should be aware about the latest therapeutic management of chlamy‐
dial cervicitis and PID. Different antibiotics such as azithromycin, doxycycline, ofloxacin,
erythromycin, and amoxicillin may be useful for treating genital chlamydial infections [131].
The antibiotic selection depends on the characteristics of the drug itself like pharmacokinetics,
half-life, and bioavailability, concentration in mucous membranes and genital tissues, devel‐
opment of gastrointestinal tract side effects, safe use in pregnancy, as well as, the characteristics
of the host and the clinical course of chlamydial infection. The effectiveness of therapy relies
on timely treating sex partners and to abstain from sexual intercourse until completing the
whole antibiotic scheme.
Unceasing efforts are conducted for the development of a chlamydial vaccine. Nevertheless,
until now, no effective chlamydial vaccines are available. The knowledge of bacterial factors
involved in pathogenicity will help in addressing optimal vaccine design that prevents not
only chlamydial infection but also progression to infertility.
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